Revvity, Inc. announced the launch of its EONIS Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns. For both inherited conditions, immediate detection is critical to advancing a positive outcome. For SMA, disease modifying therapies exist to stop progression of disease, and for SCID, immunoglobulin treatments combined with stem cell therapies can potentially cure a child, if intervention comes in time.

However, to date, molecular testing for these and other congenital disorders is relatively low, due in part to cost restrictions and the technical expertise required to perform and interpret these tests. The EONIS Q system simplifies and streamlines molecular testing for SMA and SCID with an innovative workflow, inclusive of the EONIS Q96 instrument, the EONIS? SCID-SMA kit and dedicated EONIS EASI?

software. Turnaround time for the EONIS Q workflow from sample-in to result is approximately three hours, and compared to conventional wet qPCR solutions, the system exceeds industry standards in software capability. There are no wash steps required and fewer pipetting and centrifuging steps involved, further reducing hands-on time.

Compared to other methods, the EONIS Q system uses fewer consumables and one-time use plasticware, further optimizing resource and cost efficiencies for labs looking to adopt the system. The compact size and smaller physical footprint of the EONIS Q workflow is ideal for all lab sizes, while offering additional benefits for low- and medium-throughput labs, including those without a PCR clean room.